Loading news...
NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Procept BioRobotics set aggressive revenue targets while a internal pricing change was already undercutting realized sales NEW YORK, March 18, 2026 /PRNewswire/ -- Procept BioRobotics (NASDAQ: PRCT) guided investors toward $325.5 million in full-year 2025 revenue -- representing 45% growth -- then delivered $308.1 million, a $17.4 million shortfall that sent shares down more than 15%. Shareholders who lost money on PRCT are encouraged to submit their information now.
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into PROCEPT BioRobotics Corporation (NASDAQ: PRCT) ("PROCEPT BioRobotics Corporation") concerning potential violations of the federal securities laws. On the Q3 2025 earnings call on November 4, 2025, CFO Kevin Waters reaffirmed the $325.5 million revenue target and stated the company was "maintaining handpiece average selling prices to be approximately $3,200.
ArrowMark Colorado Holdings LLC grew its position in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) by 229.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,128,288 shares of the company's stock after purchasing an additional 786,094 shares during
NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company's next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH).
Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story NEW YORK, March 11, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) lost more than 15% of their investment value after the Company disclosed financial results that diverged sharply from the figures management had presented. Those who suffered losses are encouraged to submit their information here.
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PROCEPT BIOROBOTICS CORPORATION (PRCT) CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PROCEPT BIOROBOTICS CORPORATION (PRCT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discus.
PROCEPT BioRobotics Corporation (NASDAQ: PRCT - Get Free Report) Director Antal Rohit Desai acquired 98,699 shares of the company's stock in a transaction that occurred on Monday, March 9th. The stock was purchased at an average price of $24.55 per share, for a total transaction of $2,423,060.45. Following the acquisition, the director directly owned 426,262 shares
PROCEPT BioRobotics Corporation (NASDAQ: PRCT - Get Free Report) Director Antal Rohit Desai bought 160,317 shares of the business's stock in a transaction that occurred on Friday, March 6th. The stock was acquired at an average cost of $23.59 per share, for a total transaction of $3,781,878.03. Following the completion of the purchase, the director directly
PROCEPT BioRobotics Corporation (NASDAQ: PRCT - Get Free Report) Director Antal Rohit Desai purchased 167,246 shares of PROCEPT BioRobotics stock in a transaction dated Thursday, March 5th. The stock was bought at an average price of $25.58 per share, for a total transaction of $4,278,152.68. Following the completion of the transaction, the director directly owned 167,246
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PROCEPT BIOROBOTICS CORPORATION (PRCT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On February 25, 2026, Procept reported fo.
New York, New York--(Newsfile Corp. - March 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into PROCEPT BioRobotics Corporation ("PROCEPT BioRobotics Corporation") (NASDAQ: PRCT) concerning potential violations of the federal securities laws. On the Q3 2025 earnings call on November 4, 2025, CFO Kevin Waters reaffirmed the $325.5 million revenue target and stated the company was "maintaining handpiece average selling prices to be approximately $3,200.
LOS ANGELES--(BUSINESS WIRE)---- $PRCT--PRCT Investors Have Opportunity to Join PROCEPT BioRobotics Corporation Fraud Investigation with the Schall Law Firm.
PROCEPT BioRobotics Corporation (NASDAQ: PRCT - Get Free Report)'s stock price fell 6.9% during trading on Friday. The company traded as low as $23.59 and last traded at $23.61. 229,988 shares were traded during mid-day trading, a decline of 85% from the average session volume of 1,577,030 shares. The stock had previously closed at $25.35.
PROCEPT BioRobotics Corporation (PRCT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.